English
简体中文
Total: £ 56.28
Published Date: 2025-09-18 | Pages: 69 | Tables: 75 | Pharma & Healthcare
The global market for Multiple Myeloma Monoclonal Antibody Drugs was valued at US$ 1251 million in the year 2024 and is projected to reach a revised size of US$ 2030 million by 2031, growing at a CAGR of 7.1% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Multiple Myeloma Monoclonal Antibody Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Multiple Myeloma Monoclonal Antibody Drugs are biologic therapies specifically designed to target antigens expressed on multiple myeloma cells, including Daratumumab, Elotuzumab, and Isatuximab. These drugs function either by directly inducing cancer cell death or by recruiting the immune system to attack malignant cells. The production of these drugs relies on upstream raw materials such as recombinant DNA constructs, mammalian cell lines (commonly CHO cells), culture media components including amino acids, vitamins, and serum, as well as purification resins. Key components in the manufacturing process include protein A affinity columns, filtration membranes, and formulation excipients for stabilization. Leading suppliers in this field include Janssen Biotech (Johnson & Johnson) for Daratumumab, Bristol Myers Squibb/AbbVie for Elotuzumab, and Sanofi for Isatuximab, all of which maintain integrated capabilities from biologics development and GMP manufacturing to global distribution. In 2024, the global sales volume of multiple myeloma monoclonal antibody drugs amounted to 582,000 units, with an average price of $2,150 per unit.
Regional Market Landscape
The global multiple myeloma monoclonal antibody drug market exhibits a clear regional concentration, with North America accounting for 55% of the market, Europe 20%, Asia-Pacific 15%, and Latin America along with the Middle East and Africa combined at 10%. North America’s dominance stems from a mature healthcare system, a highly developed biopharmaceutical industry, and strong patient purchasing power. Europe relies on innovative drug approval frameworks and comprehensive insurance coverage in countries such as Germany, France, and the United Kingdom. The Asia-Pacific market is growing rapidly, driven by Japan, China, and South Korea advancing clinical trials and market access. Latin America and the Middle East and Africa remain smaller markets but show stable growth due to improvements in chronic disease management and healthcare infrastructure.
Major Manufacturers and Industry Competition
The leading manufacturers of multiple myeloma monoclonal antibody drugs include Janssen Biotech, Bristol Myers Squibb, Sanofi. Upstream raw materials and critical components are highly concentrated, relying on recombinant DNA constructs, CHO cell lines, culture media, and purification resins, with protein A affinity columns, filtration membranes, and excipients serving as key production elements, and suppliers such as Cytiva, Sartorius, and Merck KGaA holding leading positions. Downstream, the market is concentrated in hospitals, specialty clinics, and distribution channels, with manufacturers leveraging contract manufacturing and global logistics to maintain supply stability. Industry competition focuses on product differentiation and combination therapy strategies, with companies expanding indications, optimizing dosing regimens, and developing bispecific antibodies to sustain market share.
Technology Trends and Innovation Directions
Current technology trends focus on enhancing antibody specificity and potency, reducing immunogenicity, and improving administration convenience. Bispecific antibodies and antibody-drug conjugates are emerging as key innovation areas, combining immune cell recruitment and tumor-targeting mechanisms. Pharmaceutical companies continue to optimize manufacturing processes to increase expression efficiency and purification yield while adopting automation and digital tools to improve quality control and regulatory compliance.
Policy and Industry Development Drivers
Policy and regulatory frameworks play a crucial role in market development. Accelerated drug approval pathways, insurance coverage, and clinical trial support policies drive rapid industry expansion. Intellectual property protection and biologics patent systems secure returns on R&D investment, while initiatives promoting local innovative drug registration and market access provide clear competitive rules for multinational companies. Market growth is also fueled by rising global healthcare demand, population aging, and improvements in cancer screening and treatment capabilities.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Multiple Myeloma Monoclonal Antibody Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Myeloma Monoclonal Antibody Drugs.
The Multiple Myeloma Monoclonal Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Multiple Myeloma Monoclonal Antibody Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Myeloma Monoclonal Antibody Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Johnson & Johnson
Sanofi
Bristol Myers Squibb
Segment by Type
Daratumumab
Elotuzumab
Isatuximab
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Multiple Myeloma Monoclonal Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Multiple Myeloma Monoclonal Antibody Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Multiple Myeloma Monoclonal Antibody Drugs Market Overview
1.1 Product Definition
1.2 Multiple Myeloma Monoclonal Antibody Drugs by Type
1.2.1 Global Multiple Myeloma Monoclonal Antibody Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Daratumumab
1.2.3 Elotuzumab
1.2.4 Isatuximab
1.3 Multiple Myeloma Monoclonal Antibody Drugs by Application
1.3.1 Global Multiple Myeloma Monoclonal Antibody Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Multiple Myeloma Monoclonal Antibody Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue 2020-2031
1.4.2 Global Multiple Myeloma Monoclonal Antibody Drugs Sales 2020-2031
1.4.3 Global Multiple Myeloma Monoclonal Antibody Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Multiple Myeloma Monoclonal Antibody Drugs Market Competition by Manufacturers
2.1 Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Multiple Myeloma Monoclonal Antibody Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Multiple Myeloma Monoclonal Antibody Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multiple Myeloma Monoclonal Antibody Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Myeloma Monoclonal Antibody Drugs, Product Type & Application
2.7 Global Key Manufacturers of Multiple Myeloma Monoclonal Antibody Drugs, Date of Enter into This Industry
2.8 Global Multiple Myeloma Monoclonal Antibody Drugs Market Competitive Situation and Trends
2.8.1 Global Multiple Myeloma Monoclonal Antibody Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Multiple Myeloma Monoclonal Antibody Drugs Players Market Share by Revenue
2.8.3 Global Multiple Myeloma Monoclonal Antibody Drugs Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Multiple Myeloma Monoclonal Antibody Drugs Market Scenario by Region
3.1 Global Multiple Myeloma Monoclonal Antibody Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Region: 2020-2031
3.2.1 Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Region: 2020-2025
3.2.2 Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Region: 2026-2031
3.3 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region: 2020-2031
3.3.1 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region: 2020-2025
3.3.2 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region: 2026-2031
3.4 North America Multiple Myeloma Monoclonal Antibody Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Myeloma Monoclonal Antibody Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2020-2031)
3.4.3 North America Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Multiple Myeloma Monoclonal Antibody Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Myeloma Monoclonal Antibody Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2020-2031)
3.5.3 Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Multiple Myeloma Monoclonal Antibody Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Myeloma Monoclonal Antibody Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2020-2031)
3.7.3 Latin America Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2020-2031)
4.1.1 Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2020-2025)
4.1.2 Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2026-2031)
4.1.3 Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type (2020-2031)
4.2 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Type (2020-2031)
4.2.1 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Type (2020-2025)
4.2.2 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Type (2026-2031)
4.2.3 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Multiple Myeloma Monoclonal Antibody Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2020-2031)
5.1.1 Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2020-2025)
5.1.2 Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2026-2031)
5.1.3 Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Application (2020-2031)
5.2 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Application (2020-2031)
5.2.1 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Application (2020-2025)
5.2.2 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Application (2026-2031)
5.2.3 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Multiple Myeloma Monoclonal Antibody Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Company Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Multiple Myeloma Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Johnson & Johnson Multiple Myeloma Monoclonal Antibody Drugs Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Multiple Myeloma Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Multiple Myeloma Monoclonal Antibody Drugs Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Bristol Myers Squibb
6.3.1 Bristol Myers Squibb Company Information
6.3.2 Bristol Myers Squibb Description and Business Overview
6.3.3 Bristol Myers Squibb Multiple Myeloma Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Bristol Myers Squibb Multiple Myeloma Monoclonal Antibody Drugs Product Portfolio
6.3.5 Bristol Myers Squibb Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Myeloma Monoclonal Antibody Drugs Industry Chain Analysis
7.2 Multiple Myeloma Monoclonal Antibody Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Myeloma Monoclonal Antibody Drugs Production Mode & Process Analysis
7.4 Multiple Myeloma Monoclonal Antibody Drugs Sales and Marketing
7.4.1 Multiple Myeloma Monoclonal Antibody Drugs Sales Channels
7.4.2 Multiple Myeloma Monoclonal Antibody Drugs Distributors
7.5 Multiple Myeloma Monoclonal Antibody Drugs Customer Analysis
8 Multiple Myeloma Monoclonal Antibody Drugs Market Dynamics
8.1 Multiple Myeloma Monoclonal Antibody Drugs Industry Trends
8.2 Multiple Myeloma Monoclonal Antibody Drugs Market Drivers
8.3 Multiple Myeloma Monoclonal Antibody Drugs Market Challenges
8.4 Multiple Myeloma Monoclonal Antibody Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Multiple Myeloma Monoclonal Antibody Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Multiple Myeloma Monoclonal Antibody Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Multiple Myeloma Monoclonal Antibody Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Multiple Myeloma Monoclonal Antibody Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Multiple Myeloma Monoclonal Antibody Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Multiple Myeloma Monoclonal Antibody Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Multiple Myeloma Monoclonal Antibody Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Multiple Myeloma Monoclonal Antibody Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Multiple Myeloma Monoclonal Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Myeloma Monoclonal Antibody Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Multiple Myeloma Monoclonal Antibody Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Region (2020-2025) & (K Units)
Table 18. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Region (2026-2031) & (K Units)
Table 20. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2020-2025) & (K Units)
Table 27. North America Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2026-2031) & (K Units)
Table 28. North America Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2020-2025) & (K Units)
Table 32. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2026-2031) & (K Units)
Table 33. Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units) by Type (2020-2025)
Table 51. Global Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units) by Type (2026-2031)
Table 52. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Multiple Myeloma Monoclonal Antibody Drugs Price (US$/Unit) by Type (2020-2025)
Table 59. Global Multiple Myeloma Monoclonal Antibody Drugs Price (US$/Unit) by Type (2026-2031)
Table 60. Global Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units) by Application (2020-2025)
Table 61. Global Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units) by Application (2026-2031)
Table 62. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Multiple Myeloma Monoclonal Antibody Drugs Price (US$/Unit) by Application (2020-2025)
Table 69. Global Multiple Myeloma Monoclonal Antibody Drugs Price (US$/Unit) by Application (2026-2031)
Table 70. Johnson & Johnson Company Information
Table 71. Johnson & Johnson Description and Business Overview
Table 72. Johnson & Johnson Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Johnson & Johnson Multiple Myeloma Monoclonal Antibody Drugs Product
Table 74. Johnson & Johnson Recent Developments/Updates
Table 75. Sanofi Company Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Sanofi Multiple Myeloma Monoclonal Antibody Drugs Product
Table 79. Sanofi Recent Developments/Updates
Table 80. Bristol Myers Squibb Company Information
Table 81. Bristol Myers Squibb Description and Business Overview
Table 82. Bristol Myers Squibb Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Bristol Myers Squibb Multiple Myeloma Monoclonal Antibody Drugs Product
Table 84. Bristol Myers Squibb Recent Developments/Updates
Table 85. Key Raw Materials Lists
Table 86. Raw Materials Key Suppliers Lists
Table 87. Multiple Myeloma Monoclonal Antibody Drugs Distributors List
Table 88. Multiple Myeloma Monoclonal Antibody Drugs Customers List
Table 89. Multiple Myeloma Monoclonal Antibody Drugs Market Trends
Table 90. Multiple Myeloma Monoclonal Antibody Drugs Market Drivers
Table 91. Multiple Myeloma Monoclonal Antibody Drugs Market Challenges
Table 92. Multiple Myeloma Monoclonal Antibody Drugs Market Restraints
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Product Picture of Multiple Myeloma Monoclonal Antibody Drugs
Figure 2. Global Multiple Myeloma Monoclonal Antibody Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Multiple Myeloma Monoclonal Antibody Drugs Market Share by Type: 2024 & 2031
Figure 4. Daratumumab Product Picture
Figure 5. Elotuzumab Product Picture
Figure 6. Isatuximab Product Picture
Figure 7. Global Multiple Myeloma Monoclonal Antibody Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Multiple Myeloma Monoclonal Antibody Drugs Market Share by Application: 2024 & 2031
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Multiple Myeloma Monoclonal Antibody Drugs Market Size (2020-2031) & (US$ Million)
Figure 13. Global Multiple Myeloma Monoclonal Antibody Drugs Sales (2020-2031) & (K Units)
Figure 14. Global Multiple Myeloma Monoclonal Antibody Drugs Average Price (US$/Unit) & (2020-2031)
Figure 15. Multiple Myeloma Monoclonal Antibody Drugs Report Years Considered
Figure 16. Multiple Myeloma Monoclonal Antibody Drugs Sales Share by Manufacturers in 2024
Figure 17. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Share by Manufacturers in 2024
Figure 18. Global 5 and 10 Largest Multiple Myeloma Monoclonal Antibody Drugs Players: Market Share by Revenue in Multiple Myeloma Monoclonal Antibody Drugs in 2024
Figure 19. Multiple Myeloma Monoclonal Antibody Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 20. Global Multiple Myeloma Monoclonal Antibody Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 21. North America Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country (2020-2031)
Figure 22. North America Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Country (2020-2031)
Figure 23. United States Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 24. Canada Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country (2020-2031)
Figure 26. Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Country (2020-2031)
Figure 27. Germany Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. France Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. U.K. Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Italy Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Russia Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Region (2020-2031)
Figure 33. Asia Pacific Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Region (2020-2031)
Figure 34. China Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Japan Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. South Korea Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. India Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Australia Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. China Taiwan Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Latin America Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country (2020-2031)
Figure 42. Latin America Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Country (2020-2031)
Figure 43. Mexico Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Brazil Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Argentina Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Colombia Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Country (2020-2031)
Figure 49. Turkey Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of Multiple Myeloma Monoclonal Antibody Drugs by Type (2020-2031)
Figure 53. Global Revenue Market Share of Multiple Myeloma Monoclonal Antibody Drugs by Type (2020-2031)
Figure 54. Global Multiple Myeloma Monoclonal Antibody Drugs Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of Multiple Myeloma Monoclonal Antibody Drugs by Application (2020-2031)
Figure 56. Global Revenue Market Share of Multiple Myeloma Monoclonal Antibody Drugs by Application (2020-2031)
Figure 57. Global Multiple Myeloma Monoclonal Antibody Drugs Price (US$/Unit) by Application (2020-2031)
Figure 58. Multiple Myeloma Monoclonal Antibody Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
